Skip to main content
NatCon25 Main banner
Back

    Clinical Practices

    Clinical Practices, Recovery and Social Supports

    E19 - Measuring the Impact of Long-acting Medications

    Monday, May 5, 2025
    4:30 PM – 5:30 PM ET
    Location: 117
    NASW CCB ACCME ANCC APA NY-SW NY-MHC NADAAC NBCC
    LAMs are widely available and have research-proven clinical benefits compared to oral medications for individuals with schizophrenia, schizoaffective disorder or bipolar disorder. These include a significant delay and reduction in relapse, particularly in patients with early-phase or first-episode schizophrenia and a lower risk of discontinuation and frequency of hospitalizations compared with oral antipsychotics. This presentation will explore the recent data trends on LAM's impact.

    Learning Objectives:

    • Examine the current utilization rates of LAMs
    • Explore the impact LAMs are having on individuals with psychotic disorders.
    • Identify ways to expand the use of LAMs.